Product
RQ3013
2 clinical trials
1 indication
Indication
COVID-19Clinical trial
Randomized, Blinded, Positive Control Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine (RQ3013) in Healthy Adults Aged 18-59 YearsStatus: Not yet recruiting, Estimated PCD: 2023-02-01